Search research articles
Contact Us
Filters
Showing results (661-670 of 1,095) with videos related to
Page
of 110
Sort By:
Tumori
|
May 18, 2021
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
Roberta Minari, Francesco Bonatti, Giulia Mazzaschi, et al.
Exploration of Targeted Anti-Tumor Therapy
|
September 18, 2023
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity
Melissa Bersanelli, Letizia Gnetti, Francesco Paolo Pilato, et al.
The Lancet Regional Health. Europe
|
September 22, 2025
Estimating the impact of displacement from Ukraine on HBV and HCV prevalence among migrants in the European Union, 2024: a modeling study
Devin M Razavi-Shearer, Loreta A Kondili, Samantha Hall, et al.
Journal of Clinical Gastroenterology
|
November 2, 2013
Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response
Stuart C Gordon, K Rajender Reddy, Ira M Jacobson, et al.
Cancers
|
November 13, 2021
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
Michela Verzè, Roberta Minari, Letizia Gnetti, et al.
BMC Infectious Diseases
|
September 5, 2018
Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus
María Eugenia Soria, Josep Gregori, Qian Chen, et al.
The American Journal of Gastroenterology
|
July 9, 2009
Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients
Erik H C J Buster, Hajo J Flink, Halis Simsek, et al.
Hepatology Communications
|
February 26, 2025
Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B
Florian van Bömmel, Thierry Verbinnen, Kosh Agarwal, et al.
Alimentary Pharmacology & Therapeutics
|
August 28, 2024
Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective-prospective study
Elena Vargas-Accarino, Ariadna Rando-Segura, Adriana Palom, et al.
Gastroenterology
|
December 10, 2013
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C
Maria Buti, Kosh Agarwal, Yves Horsmans, et al.
Page
of 110
Search research articles
Search
Showing results (661-670 of 1,095) with videos related to
Sort By:
Page
of 110
Tumori
|
May 18, 2021
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
Roberta Minari, Francesco Bonatti, Giulia Mazzaschi, et al.
Exploration of Targeted Anti-Tumor Therapy
|
September 18, 2023
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity
Melissa Bersanelli, Letizia Gnetti, Francesco Paolo Pilato, et al.
The Lancet Regional Health. Europe
|
September 22, 2025
Estimating the impact of displacement from Ukraine on HBV and HCV prevalence among migrants in the European Union, 2024: a modeling study
Devin M Razavi-Shearer, Loreta A Kondili, Samantha Hall, et al.
Journal of Clinical Gastroenterology
|
November 2, 2013
Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response
Stuart C Gordon, K Rajender Reddy, Ira M Jacobson, et al.
Cancers
|
November 13, 2021
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
Michela Verzè, Roberta Minari, Letizia Gnetti, et al.
BMC Infectious Diseases
|
September 5, 2018
Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus
María Eugenia Soria, Josep Gregori, Qian Chen, et al.
The American Journal of Gastroenterology
|
July 9, 2009
Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients
Erik H C J Buster, Hajo J Flink, Halis Simsek, et al.
Hepatology Communications
|
February 26, 2025
Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B
Florian van Bömmel, Thierry Verbinnen, Kosh Agarwal, et al.
Alimentary Pharmacology & Therapeutics
|
August 28, 2024
Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective-prospective study
Elena Vargas-Accarino, Ariadna Rando-Segura, Adriana Palom, et al.
Gastroenterology
|
December 10, 2013
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C
Maria Buti, Kosh Agarwal, Yves Horsmans, et al.
Page
of 110